Blanca Elizabeth Ruiz Alvarez | Microbiome | Young Scientist Award

Published on by Cell Biologist

Mrs. Blanca Elizabeth Ruiz Alvarez | Microbiome | Young Scientist Award

Mrs. Blanca Elizabeth Ruiz Alvarez, université laval, Canada

Blanca Elizabeth Ruiz Alvarez is a passionate and multilingual health sciences researcher with over 13 years of experience, including more than 4 years in clinical research. Currently pursuing dual PhDs in Plant Biology at Université Laval and in Biotechnology Innovation at CIATEJ, Mexico, Blanca blends cutting-edge science with applied biotechnology. Her work emphasizes the role of bioactive compounds, gut microbiota, and AI-based diagnostics in human health. A published author in high-impact journals and co-inventor of several patents, she has presented her research internationally and advised research-driven companies such as Grupo Mabiosis. Blanca is fluent in French, English, and Spanish, enabling her to effectively communicate and collaborate in global scientific contexts. Her commitment to scientific excellence, innovation, and societal impact makes her a standout among emerging researchers.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Exceptional Academic Background
    Blanca is pursuing dual PhD programs in Plant Biology (Université Laval, Canada) and Biotechnology Innovation (CIATEJ, Mexico), showcasing academic rigor and international collaboration.

  2. Multilingual & Multicultural
    Fluent in French, English, and Spanish, enabling her to communicate and collaborate globally—an asset in modern scientific research environments.

  3. Innovative Research Focus
    Her work integrates bioactive compounds, gut microbiota, microbiome diagnostics, and AI/mathematical modeling—fields that align with global research trends in personalized health, nutrition, and biotechnology.

  4. Impressive Research Output
    Blanca has authored multiple peer-reviewed publications, book chapters, and is co-inventor on several international patents, indicating both scientific innovation and practical application.

  5. Leadership and Collaboration
    Serves as a Postgraduate Research Assistant and Scientific Advisor, managing multidisciplinary research projects and mentoring younger scientists—key traits for a future leader in science.

🔍 Areas for Improvement:

  • Public Science Communication
    Although Blanca is a strong scientific communicator, more active public outreach or science popularization efforts (e.g., TEDx talks, public blogs) could boost her visibility and societal impact.

  • Industry-Academia Collaboration
    She could enhance the translational value of her research through stronger industry partnerships or startup initiatives in biotech or diagnostics sectors.

🎓 Education:

Blanca holds a Master’s degree in Medical and Pharmaceutical Biotechnology, which laid the foundation for her specialization in bioactive compounds and clinical applications. She is currently completing dual PhD programs—one in Plant Biology at Université Laval, Québec, Canada, and another in Biotechnology Innovation Sciences at CIATEJ, Guadalajara, Mexico. Her doctoral research is highly interdisciplinary, integrating fields such as molecular biology, AI-assisted modeling, microbiology, and preclinical testing. Through these programs, she has gained expertise in both fundamental plant-based biocompounds and their translational potential in human health. Her international education trajectory also reflects her adaptability and collaborative research mindset. Blanca’s academic training emphasizes not just scientific rigor but also cross-cultural communication and innovation-driven thinking—traits essential for cutting-edge biomedical research in today’s interconnected world.

🧪 Experience:

Blanca’s experience spans over 13 years in scientific research, including 4+ years in clinical and biomedical fields. Since 2020, she has worked as a Postgraduate Research Assistant at INAF, Université Laval, in collaboration with CIATEJ, Mexico. Her role involves experimental design, data modeling using bioinformatics and AI, and presenting findings at international forums. Additionally, she serves as a Scientific Advisor to Grupo Mabiosis, overseeing project planning and scientific protocol development. Blanca is skilled in in vitro biological evaluations, microbiology techniques, and protocol optimization. She is also a proficient scientific communicator, contributing to journal articles, book chapters, and conference proceedings. With extensive experience managing research projects from conceptualization to publication and regulatory filings, Blanca exemplifies leadership and innovation in her field. Her blend of academic insight and real-world application gives her a unique edge in the research landscape.

🔬 Research Focus:

Blanca’s research revolves around the interaction between bioactive compounds and the gut microbiota, with a strong emphasis on prebiotics, synbiotics, and the health impacts of polyphenols and flavonoids. She investigates the biological effects of natural compounds using in vitro models such as SHIME® and twin-M-SHIME®, alongside advanced microbiological and analytical techniques. Blanca incorporates AI and bioinformatics to model gut health and predict microbiota behavior in response to dietary interventions. Her recent studies explore how modified flavonoids enhance microbial fermentation and contribute to gut-brain and gut-immune axis functions. Blanca also works on mathematical modeling to support diagnostic tools using microbiome signatures—an area backed by patent filings. This research bridges plant biology, pharmaceutical biotechnology, and nutritional sciences, offering innovative strategies for disease prevention and health optimization. Her ultimate aim is to develop personalized health interventions based on microbiome composition and functional dietary compounds.

📚 Publications Top Notes:

🔬 Novel acylated naringin enhances propionate release and stimulates the growth of flavanone-metabolizing bacteria in an in vitro batch fermentation model (Life, 2025)
🧫 Prebiotic-like Effects of Proanthocyanidin-Rich Aronia Extract Supplementation on Gut Microbiota Composition and Function in the Twin-M-SHIME® model (Pharmaceuticals, 2025)
🦠 Anticandidal and Antibiofilm Effect of Synbiotics including Probiotics and Inulin-Type Fructans (Antibiotics, 2022)
👧 Digestibility and Bioaccessibility of Leaf Protein Concentrates and their Impact on Children Gut Microbiota (Waste and Biomass Valorization, 2022)
🧠 A Diagnostic and Treatment System Based on the Gut Microbiota Balance (Novel Techniques in Nutrition and Food Science, 2019 – Commentary)
🍃 In vitro evaluation of prebiotic activity, pathogen inhibition and enzymatic metabolism of intestinal bacteria in the presence of fructans extracted from agave: A comparison based on polymerization degree (LWT, 2018)
📖 Book Chapter: “Managing Bioactive Substances”, “Nutritional Intervention: A Practical Perspective”, Universidad de Guadalajara (in publication)

🧾 Conclusion:

Blanca Elizabeth Ruiz Alvarez stands out as a highly qualified and driven young scientist with a solid track record of scientific excellence, innovation, and interdisciplinary collaboration. Her work directly addresses critical global challenges in health, nutrition, and sustainable biotechnology, supported by her scholarly outputs and international research roles.

Paola Zagami | Cancer Cell Biology | Young Scientist Award

Published on by Cell Biologist

Dr. Paola Zagami | Cancer Cell Biology | Young Scientist Award

Dr. Paola Zagami , IEO european institute of oncology University of Milan , Italy

Dr. Paola Zagami is an accomplished Italian physician and medical oncologist currently working at the European Institute of Oncology (IEO) in Milan. She specializes in clinical and research oncology, focusing on breast cancer. With a strong academic background and passion for advancing cancer treatment, Dr. Zagami has contributed to numerous studies on innovative therapies, particularly immunotherapy and endocrine treatments in breast cancer. She is recognized for her expertise in cancer genomics and the impact of immune checkpoint inhibitors in cancer treatment. Dr. Zagami’s work reflects a blend of clinical practice and research, as she actively collaborates with experts in the oncology field to improve patient outcomes.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Paola Zagami is an exceptional candidate for the Research for Young Scientist Award due to her profound contributions to oncology research, particularly in breast cancer treatment and clinical trials. Her work on immune checkpoint inhibitors, endocrine therapies, and the genomics of breast cancer demonstrates her expertise in precision oncology. Dr. Zagami has been involved in high-impact publications and collaborative international studies, such as her work on metastatic triple-negative breast cancer and the development of novel cancer therapies. Her clinical and research skills, combined with her ability to contribute to the scientific community through publications and awards, make her a highly qualified and promising young scientist. Furthermore, her commitment to gender equity in pharmacological research and clinical trials aligns with the future direction of oncology research, making her a strong contender for the award.

Areas for Improvement:

While Dr. Zagami has made significant strides in breast cancer research, there are opportunities to broaden her research focus to include other cancer types, enabling her to contribute to a wider array of oncological studies. Additionally, further involvement in leading large-scale clinical trials could enhance her leadership in the field. Expanding her research network internationally could facilitate more diverse collaborations and broader research impact.

Education:

Dr. Zagami earned her medical degree (MD) and has since pursued extensive education in the field of oncology. In 2021, she received a scholarship from the IEO-Monzino Foundation, focusing on clinical research in oncology. She further honed her expertise by earning the AMMI award in 2023 for her work on gender equity in pharmacological research. This education in clinical research positions Dr. Zagami as a thought leader in her field, with a commitment to investigating new treatments and approaches in cancer care.

Experience:

Dr. Zagami’s professional career began as an oncological clinical researcher, where she focused on the development of targeted therapies and the clinical impact of cancer treatments. Since 2024, she has been serving as a medical oncologist at the European Institute of Oncology (IEO) in Milan, contributing to both clinical and research activities. Throughout her career, Dr. Zagami has gained experience in advanced oncology treatments, particularly in immunotherapy and endocrine therapies for breast cancer. She works closely with interdisciplinary teams to design and conduct clinical trials, improving personalized cancer care. Dr. Zagami’s research collaborations have resulted in several publications in prestigious journals, reflecting her expertise and commitment to enhancing cancer treatment strategies.

Experience:

Dr. Zagami’s professional career began as an oncological clinical researcher, where she focused on the development of targeted therapies and the clinical impact of cancer treatments. Since 2024, she has been serving as a medical oncologist at the European Institute of Oncology (IEO) in Milan, contributing to both clinical and research activities. Throughout her career, Dr. Zagami has gained experience in advanced oncology treatments, particularly in immunotherapy and endocrine therapies for breast cancer. She works closely with interdisciplinary teams to design and conduct clinical trials, improving personalized cancer care. Dr. Zagami’s research collaborations have resulted in several publications in prestigious journals, reflecting her expertise and commitment to enhancing cancer treatment strategies.

Research Focus:

Dr. Zagami’s research focus is primarily centered around the treatment of breast cancer, particularly in the areas of immunotherapy, endocrine therapy, and personalized medicine. She has been involved in research on immune checkpoint inhibitors for metastatic triple-negative breast cancer and the clinical implications of genomic alterations in breast cancer. Dr. Zagami is also dedicated to investigating the safety and efficacy of novel cancer therapies, particularly in early-phase clinical trials. Her research interests also include the study of gender equity in pharmacological research and the integration of molecular diagnostics in clinical trials for metastatic breast cancer. She is committed to advancing precision oncology by studying the genetic and clinical landscape of breast cancer to enhance patient outcomes and treatment strategies.

Publications Top Notes:

  1. Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?
  2. Triple negative breast cancer: pitfalls and progress.
  3. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
  4. Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives.
  5. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.
  6. Immunotherapy for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.

Conclusion:

Dr. Paola Zagami is undoubtedly a rising star in the field of oncology. Her combination of clinical experience, research accomplishments, and passion for improving cancer treatments positions her as a highly deserving candidate for the Research for Young Scientist Award. As she continues to advance her work in oncology, her future contributions have the potential to significantly impact cancer care and research globally. With some further expansion in her research focus and leadership roles, Dr. Zagami is poised to be an influential figure in oncology for years to come.